Ligand
Executive Summary
Expands screening for anti-cancer drugs to certain samples contained within the Natural Products Repository of the National Cancer Institute under an agreement with NCI announced May 3. Ligand plans to use its proprietary screening technology to identify potential small molecule cancer therapeutics that target intracellular receptors and will concentrate its efforts on the retinoid and sex steroid receptors.